Svelte Medical Systems, Inc. Announces Treatment of First Patient in the ACES Effectiveness Study

NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--Svelte® Medical Systems today announced treatment of the first patient in the ACES (Acrobat Coronary stent system effectiveness European Study) clinical trial by Victor Legrand, MD, PhD at CHU Liege in Liege, Belgium. ACES is a randomized, controlled study designed to demonstrate the positive clinical benefit and impact on resource utilization of the Svelte Acrobat Integrated Delivery System (IDSTM) compared with conventional coronary stent devices in patients with lesions eligible for direct stenting. Up to 300 patients will be enrolled in the study at 12 sites in France, Belgium and Spain. A fixed-wire based system, the Svelte coronary stent IDS is low profile and highly flexible, navigating through the vasculature similar to a traditional guidewire, allowing physicians to ‘direct-stent’ coronary artery lesions and eliminate several steps in their current stenting procedures. Non-randomized data presented at medical symposia earlier this year suggest the Svelte IDS significantly reduces radiation exposure, contrast use, adjunctive interventional product use and overall procedure time when compared with conventional stent systems.

Back to news